Should I buy or sell BiomX stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHGE shares. View PHGE analyst ratings or view top-rated stocks .

What is BiomX's stock price target for 2024?

1 brokerages have issued 1 year price objectives for BiomX's shares. Their PHGE share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 2,400.0% from the stock's current price. View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts .

Are investors shorting BiomX?

BiomX saw a drop in short interest in the month of December. As of December 15th, there was short interest totaling 25,300 shares, a drop of 74.3% from the November 30th total of 98,300 shares. Based on an average daily volume of 158,400 shares, the short-interest ratio is presently 0.2 days. View BiomX's Short Interest .

When is BiomX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024. View our PHGE earnings forecast .

How were BiomX's earnings last quarter?

BiomX Inc. (NYSEAMERICAN:PHGE) issued its earnings results on Tuesday, November, 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03.

How do I buy shares of BiomX?

Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:PHGE

BiomX (PHGE) Stock Price, News & Analysis

$0.28

-0.01 (-3.45%)

(As of 12/29/2023 ET)

Compare

Today's Range: $0.28
▼
$0.31
50-Day Range: N/A
52-Week Range: $0.18
▼
$0.69

Volume: 217,495 shs
Average Volume: 237,722 shs
Market Capitalization: $12.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Stock Analysis Analyst Forecasts Chart Earnings Headlines Short Interest

BiomX MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,400.0% Upside
$7.00 Price Target
Short Interest: Healthy
0.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$4,038 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.48) to ($0.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
BiomX has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, BiomX has a forecasted upside of 2,400.0% from its current price of $0.28.
Amount of Analyst Coverage
BiomX has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.06% of the outstanding shares of BiomX have been sold short.
Short Interest Ratio / Days to Cover
BiomX has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BiomX has recently decreased by 74.26%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BiomX does not currently pay a dividend.
Dividend Growth
BiomX does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHGE.

2.8

News and Social Media Coverage

News Sentiment
BiomX has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for BiomX this week, compared to 0 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BiomX insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,038.00 in company stock.
Percentage Held by Insiders
Only 4.21% of the stock of BiomX is held by insiders.
Percentage Held by Institutions
Only 36.67% of the stock of BiomX is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BiomX are expected to grow in the coming year, from ($0.48) to ($0.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BiomX is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BiomX is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BiomX has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BiomX Stock (NYSEAMERICAN:PHGE)

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

PHGE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHGE Stock News Headlines

November 30, 2023 | finance.yahoo.com

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

November 29, 2023 | benzinga.com

Why Is Bacterial Infection-Focused BiomX Stock Trading Lower Today?

December 31, 2023 | MarketBeat Internal (Ad)

Claim Your $300 MarketBeat Account Credit

Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)

November 29, 2023 | msn.com

BiomX mulls pivotal trial for antibacterial after Phase 1/2 data in cystic fibrosis

November 29, 2023 | markets.businessinsider.com

BiomX Announces Positive Results From Phase 1b/2a Study Of BX004 In Chronic Pulmonary Infections

November 23, 2023 | seekingalpha.com

BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day

November 16, 2023 | markets.businessinsider.com

Promising Clinical Trials and Financial Stability Bolster BiomX’s Buy Rating: An Analysis by Michael Higgins

November 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: BiomX (PHGE), Quoin Pharmaceuticals (QNRX) and Precigen (PGEN)

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.

October 27, 2023 | finance.yahoo.com

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference

October 18, 2023 | finance.yahoo.com

BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

October 4, 2023 | finance.yahoo.com

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

September 7, 2023 | finance.yahoo.com

BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the European Respiratory Society (ERS) International Congress 2023

September 6, 2023 | finance.yahoo.com

BiomX to Present at H.C. Wainwright 25th Annual Global Investment Conference

August 9, 2023 | finance.yahoo.com

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

August 3, 2023 | finance.yahoo.com

BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023

June 8, 2023 | finance.yahoo.com

NYSE American Initiates Delisting Proceedings for BiomX Warrants

May 15, 2023 | finance.yahoo.com

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023 | finance.yahoo.com

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

May 5, 2023 | finance.yahoo.com

BiomX Announces Second Closing of $7.5 Million Private Placement

March 27, 2023 | finance.yahoo.com

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

February 24, 2023 | msn.com

Why Is BiomX (PHGE) Stock Down 18% Today?

January 28, 2023 | msn.com

Brandon Toranzo Stands Atop Essex County

January 17, 2023 | marketwatch.com

Phage Therapy Market 2023 Expected to Reach Significant Rate by 2028

January 12, 2023 | marketwatch.com

Bacteriophage Market 2023 : Industry Scenario, Strategies, Growth Factors and Forecast to 2028

January 12, 2023 | bizjournals.com

Md. biotech Adaptive Phage Therapeutics advances fight to wipe out superbugs in cystic fibrosis

December 19, 2022 | msn.com

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session

See More Headlines

Receive PHGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BiomX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:PHGE
CUSIP: N/A
CIK: N/A
Web: www.biomx.com
Phone: 972-7-2394-2377
Fax: N/A
Employees: 54
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +2,400.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -173.61%
Return on Assets: -65.90%

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 1.98
Quick Ratio: 1.98

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.70 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 45,980,000
Free Float: 44,044,000
Market Cap: $12.87 million
Optionable: N/A
Beta: 1.25

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Jonathan Eitan Solomon MBA (Age 46)
CEO & Director
Comp: $528.57k
Ms. Marina Wolfson CPA (Age 39)
CFO & Secretary
Comp: $279.42k
Dr. Merav Bassan Ph.D. (Age 57)
Chief Development Officer
Comp: $356.59k
Prof. Rotem Sorek Ph.D.
Scientific Founder
Dr. Eran Elinav M.D.
Ph.D., Scientific Founder
Dr. Timothy K. Lu M.D. (Age 42)
Ph.D., Scientific Founder
Ms. Inbal Benjamini-Elran
C.H.R.O
Mr. Assaf Oron (Age 49)
Chief Business Officer
Comp: $352.04k

Key Competitors

View All Competitors

Insiders

Assaf Oron
Sold 10,914 shares
Total: $4,038.18 ($0.37/share)

PHGE Stock Analysis - Frequently Asked Questions

Should I buy or sell BiomX stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BiomX in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" PHGE shares.
View PHGE analyst ratings or view top-rated stocks.
What is BiomX's stock price target for 2024?: 1 brokerages have issued 1 year price objectives for BiomX's shares. Their PHGE share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 2,400.0% from the stock's current price.
View analysts price targets for PHGE or view top-rated stocks among Wall Street analysts.
Are investors shorting BiomX?: BiomX saw a drop in short interest in the month of December. As of December 15th, there was short interest totaling 25,300 shares, a drop of 74.3% from the November 30th total of 98,300 shares. Based on an average daily volume of 158,400 shares, the short-interest ratio is presently 0.2 days.
View BiomX's Short Interest.
When is BiomX's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 26th 2024.
View our PHGE earnings forecast.

How were BiomX's earnings last quarter?: BiomX Inc. (NYSEAMERICAN:PHGE) issued its earnings results on Tuesday, November, 14th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.03.
How do I buy shares of BiomX?: Shares of PHGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PHGE) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial